Insider Transactions in Q1 2024 at Genelux Corp (GNLX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2024
|
Caroline Jewett Head of Quality |
BUY
Grant, award, or other acquisition
|
Direct |
3,612
+12.24%
|
-
|
|
Mar 14
2024
|
Sean Ryder General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,270
+28.93%
|
-
|
|
Mar 14
2024
|
Tony Yu VP, Clinical Trial Operations |
BUY
Grant, award, or other acquisition
|
Direct |
11,557
+39.48%
|
-
|
|
Mar 14
2024
|
Joseph Cappello VP, Pharmaceutical Development |
BUY
Grant, award, or other acquisition
|
Direct |
11,557
+35.55%
|
-
|
|
Mar 14
2024
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
2,107
+10.4%
|
-
|
|
Mar 14
2024
|
Lourie S. Zak Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,852
+9.11%
|
-
|
|
Mar 14
2024
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
26,264
+34.35%
|
-
|
|
Feb 19
2024
|
Caroline Jewett Head of Quality |
BUY
Grant, award, or other acquisition
|
Direct |
1,143
+4.88%
|
-
|
|
Feb 19
2024
|
Sean Ryder General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,936
+17.85%
|
-
|
|
Feb 19
2024
|
Tony Yu VP, Clinical Trial Operations |
BUY
Grant, award, or other acquisition
|
Direct |
3,661
+37.27%
|
-
|
|
Feb 19
2024
|
Joseph Cappello VP, Pharmaceutical Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,661
+28.04%
|
-
|
|
Feb 19
2024
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
616
+4.23%
|
-
|
|
Feb 19
2024
|
Lourie S. Zak Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,220
+3.62%
|
-
|
|
Feb 19
2024
|
Thomas Zindrick President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,320
+26.59%
|
-
|